TORONTO, July 20, 2015 (GLOBE NEWSWIRE) -- Polydex Pharmaceuticals Limited (Pink Sheets:POLXF) (the "Company") announced that its Annual General Meeting is to be held at 10:00 am, local time, on August 28, 2015, at the principal offices of the Company located at 421 Comstock Road, Toronto, Ontario, Canada, M1L 2H5.
The Company also announced the inaugural use of e-voting and encourages registered shareholders to ensure their votes are counted by carefully following the instructions on the Notice Card, mailed on July 17, 2015, to shareholders of record as of June 17, 2015. Only holders of record of the Common Shares and the Class B Preferred Shares of the Company at the close of business on the Record Date are entitled to notice of, and to vote at, the 2015 Annual General Meeting. The Notice Card provides important instructions on how to cast your vote electronically, utilizing the InvestorVote system of the Company's Transfer Agent, Computershare.
The Company's Annual Report and Proxy Statement for the year ended January 31, 2015 are available on the Company website www.Polydex.com. The Proxy Statement contains additional information regarding the proposals to be considered and voted upon at the Annual General Meeting and shareholders are encouraged to read it in its entirety.
Shareholders are also invited to attend the Annual General Meeting and cast their votes in person at the company address provided above. Shareholders attending in person should bring the Notice Card received in the mail.
Registered shareholders possess paper share certificates registered in your name. If you are a registered shareholder you should follow the instructions on the Notice Card to cast your vote electronically.
Beneficial shareholders own shares held on their behalf by an intermediary, including securities dealers or brokers, banks, or trust companies, for example. Beneficial owners should receive an information package, including a Notice Card, from intermediaries holding shares on your behalf with instructions on how to vote or attend the Annual General Meeting in person.
George Usher, President and CEO of the Company indicated that, "We're trying something new this year. Electronic voting is becoming the standard for public companies because it is faster than regular mail; it will decrease our use of paper, and should help reduce expenses relating to the Annual General Meeting. It's also very simple, requiring just a couple of minutes to complete. We're hoping that our shareholders will embrace this method and cast their important votes online in accordance with the instructions on the Notice Card we've mailed out in place of the usual proxy and annual report materials."
The Company's publicly traded shares continue to be quoted on the OTC Pink Sheet platform (www.otcmarkets.com/stock/POLXF/quote).
The company continues full disclosure of its financial and operational results, which can be accessed by visiting the company website at www.Polydex.com. Product information is available at www.dextran.ca
Polydex Pharmaceuticals Limited, based in Toronto, Ontario, Canada, is engaged in the manufacture of bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry and also the development, manufacture and marketing of biotechnology-based products for the human pharmaceutical market. Company website: www.Polydex.com
Note: This press release may contain forward-looking statements, within the meaning of the United States Securities Act of 1933, as amended, and the United States Securities Exchange Act of 1934, as amended, regarding Polydex Pharmaceuticals Limited, including, without limitation, statements regarding expectations about future revenues or business opportunities or potential research projects. These statements are typically identified by use of words like "may", "could", "might", "expect", "anticipate", "believe", or similar words. Actual events or results may differ materially from the Company's expectations, which are subject to a number of known and unknown risks and uncertainties including but not limited to changing market conditions, future actions by the United States Food and Drug Administration or equivalent foreign regulatory authorities as results of pending or future clinical trials. Other risk factors discussed in the Company's filings with the United States Securities and Exchange Commission may also affect the actual results achieved by the Company.